TNFR1 ablation improves survival and attenuates adverse LV remodeling post-myocardial infarction in mice, potentially by modulating MMP-TIMP activity.
No takes yet. Share an insight, caveat, or question.
TNFR1 ablation merits exploration as post-MI therapy in mice; leaves open translation to human heart failure trials.
Ramani et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: